2021
Cilostazol for Secondary Stroke Prevention
de Havenon A, Sheth KN, Madsen TE, Johnston KC, Turan TN, Toyoda K, Elm JJ, Wardlaw JM, Johnston SC, Williams OA, Shoamanesh A, Lansberg MG. Cilostazol for Secondary Stroke Prevention. Stroke 2021, 52: e635-e645. PMID: 34517768, PMCID: PMC8478840, DOI: 10.1161/strokeaha.121.035002.Peer-Reviewed Original ResearchConceptsSecondary stroke preventionStroke preventionDouble-blind placebo-controlled randomized trialLargest secondary stroke prevention trialSecondary stroke prevention trialsPlacebo-controlled randomized trialStroke Prevention TrialTreatment of claudicationOpen-label designNoncardioembolic ischemic strokePeripheral arterial diseaseLong-term treatmentOnset of benefitDays of treatmentEuropean Medicines AgencyCognitive outcome dataMillions of patientsPremature trial terminationDrug discontinuationMajor bleedingGastrointestinal symptomsStroke recurrenceIschemic strokeNoncardioembolic strokeSecondary prevention
2015
Evaluation of Short-Term Changes in Serum Creatinine Level as a Meaningful End Point in Randomized Clinical Trials
Coca SG, Zabetian A, Ferket BS, Zhou J, Testani JM, Garg AX, Parikh CR. Evaluation of Short-Term Changes in Serum Creatinine Level as a Meaningful End Point in Randomized Clinical Trials. Journal Of The American Society Of Nephrology 2015, 27: 2529-2542. PMID: 26712525, PMCID: PMC4978048, DOI: 10.1681/asn.2015060642.Peer-Reviewed Original ResearchConceptsSerum creatinine levelsCreatinine levelsClinical trialsEnd pointAcute elevationRandomized trialsAcute changesPlacebo-controlled randomized trialSafety end pointRandomized clinical trialsStrong risk factorMeaningful clinical outcomesMeaningful end pointsClinical outcomesKidney functionPoor outcomeAcute increaseRisk factorsThorough literature searchObservational studyTemporary elevationMortality rateShort-term effectsPlaceboCKDCorrelates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system
Springer SA, Brown SE, Di Paola A, Altice FL. Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system. Drug And Alcohol Dependence 2015, 157: 158-165. PMID: 26560326, PMCID: PMC4675147, DOI: 10.1016/j.drugalcdep.2015.10.023.Peer-Reviewed Original ResearchConceptsAlcohol use disorderExtended-release naltrexoneOpioid use disorderXR-NTXUse disordersHIV diseaseFirst injectionDouble-blind placebo-controlled randomized trialSecond injectionPlacebo-controlled randomized trialSubstance use disordersMultivariate regression analysisTreatment of alcoholCorrelates of retentionAntiretroviral therapyStudy drugHIV infectionRandomized trialsUrine testsUrine screensEligible personsDays of releaseHazardous drinkingCocaine useDemographic features
2005
Two-year clinical follow-up of 90Sr/90 Y β-radiation versus placebo control for the treatment of in-stent restenosis
Silber S, Popma JJ, Suntharalingam M, Lansky AJ, Heuser RR, Speiser B, Teirstein PS, Bass T, O'Neill W, Lasala J, Reisman M, Sharma SK, Kuntz RE, Bonan R, Investigators F. Two-year clinical follow-up of 90Sr/90 Y β-radiation versus placebo control for the treatment of in-stent restenosis. American Heart Journal 2005, 149: 689-694. PMID: 15990754, DOI: 10.1016/j.ahj.2004.05.061.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAnticoagulantsBeta ParticlesBrachytherapyCoronary AngiographyCoronary DiseaseCoronary RestenosisDiabetes ComplicationsDisease-Free SurvivalFemaleFollow-Up StudiesHumansLife TablesMaleMiddle AgedPrognosisStentsStrontium RadioisotopesThrombophiliaTreatment OutcomeYttrium RadioisotopesConceptsMajor adverse cardiac eventsTarget vessel revascularizationStent restenosisIntracoronary brachytherapyOriginal patientsPrimary safety end pointTwo-year clinical outcomesPlacebo-controlled randomized trialEnd pointAdverse cardiac eventsPlacebo-controlled studyPrimary end pointSafety end pointKaplan-Meier analysisInitial beneficial effectsRestenosis TrialVessel revascularizationCardiac eventsPlacebo armClinical followActive treatmentClinical outcomesRandomized trialsPlacebo controlPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply